deltatrials
Terminated PHASE2 INTERVENTIONAL 3-arm NCT03376477

Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

A Randomized, Double-blind, Placebo-Controlled Phase II Trial of an Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission

Sponsor: Aduro Biotech, Inc.

Conditions Multiple Myeloma
Interventions GM-CSF vaccine Lenalidomide Placebo GM-CSF Vaccine Placebo Prevnar13 Prevnar13
Updated 17 times since 2018 Last updated: Aug 8, 2025 Started: Sep 23, 2019 Primary completion: Jan 2, 2024 Completion: May 30, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

loss of funding

Other terminated trials from Aduro Biotech, Inc.

More terminations from Aduro Biotech, Inc.

Other Multiple Myeloma trials with similar outcome

Browse all Multiple Myeloma trials

A PHASE2 clinical study on Multiple Myeloma, this trial is terminated or withdrawn. The trial is conducted by Aduro Biotech, Inc. and has accumulated 17 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Jun 2019 · 8 months · monthly snapshot~Jun 2019 – ~Aug 2019 · 2 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Jan 2020 · 4 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Feb 2022 · 13 months · monthly snapshot~Feb 2022 – ~Sep 2022 · 7 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Apr 2024 · 13 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~Jan 2025 · 2 months · monthly snapshot~Jan 2025 – ~Sep 2025 · 8 months · monthly snapshot~Sep 2025 – present · 12 months · monthly snapshot

Change History

17 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

    Status: Active Not Recruiting → Terminated

  2. Jan 2025 — Sep 2025 [monthly]

    Active Not Recruiting PHASE2

  3. Nov 2024 — Jan 2025 [monthly]

    Active Not Recruiting PHASE2

  4. Sep 2024 — Nov 2024 [monthly]

    Active Not Recruiting PHASE2

  5. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE2

▶ Show 12 earlier versions

  1. Apr 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2023 — Apr 2024 [monthly]

    Active Not Recruiting PHASE2

  3. Sep 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  4. Feb 2022 — Sep 2022 [monthly]

    Recruiting PHASE2

  5. Jan 2021 — Feb 2022 [monthly]

    Recruiting PHASE2

  6. Jan 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  7. Sep 2019 — Jan 2020 [monthly]

    Recruiting PHASE2

  8. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  9. Jun 2019 — Aug 2019 [monthly]

    Not Yet Recruiting PHASE2

    Status: Recruiting → Not Yet Recruiting

  10. Oct 2018 — Jun 2019 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  11. Jun 2018 — Oct 2018 [monthly]

    Not Yet Recruiting PHASE2

  12. Jan 2018 — Jun 2018 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Aduro Biotech, Inc.
  • Celgene
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Data source: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations